Melanoma breakthrough paves way for personalised treatment for all cancer patients

Melanoma breakthrough paves way for personalised treatment for all cancer patients

14 February 2019

Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.

The groundbreaking research, published in Cancer Cell by a team of researchers from Melanoma Institute Australia (MIA), identifies markers of response and resistance in metastatic melanoma patients.

Co-Medical Director of Melanoma Institute Australia, Professor Georgina Long, said the findings have the potential to revolutionalise how treatment is delivered for all cancer patients.

‘Immunotherapy is the new frontier of melanoma treatment, and whilst it has had astounding results for patients who respond, there has been a subset of patients who are resistant to the treatment,’ Professor Long said.

‘Being able to identify the immune markers of response takes out the guess work, and allows us to be proactive in providing the right drug treatment for the right patients. This has the potential to revolutionise how all cancers are treated around the world.’

The Melanoma Institute Australia team, led by PhD student Tuba Nur Gide and postdoctoral scientists Camelia Quek and James Wilmott, performed immune profiling on 158 tumour biopsies from melanoma patients treated with anti-PD-1 monotherapy or combined anti-PD-1 and anti-CTLA-4 therapy.

They found that genes involving immune memory and activation were higher in responders to immunotherapy, whereas non-responders showed higher levels of genes related to tumour adaptation and cancer cell survival.

Examining more closely the immune cells in the tumours of responders, a specific sub-type of T-cell was found to be correlated with response and survival. Patients with this immune cell had significant shrinkage of their tumours, and longer progression-free survival .

Non-responding patients were found to lie in two distinct groups – one that can possibly benefit from other available treatment combinations, and another that requires more research into novel treatment strategies. The first group were seen to have several other potential therapeutic targets, possibly leading to the development of individualised immunotherapy for selected patients.

‘In addition to knowing up front which patients are likely to respond to current immunotherapy treatments, these findings will also enable us to focus research efforts on developing new therapies targeting the biological markers identified in current non-responders,’ Professor Long  added.

‘The result will be personalised immunotherapy treatment for all patients, based not on their type of cancer, but based on their tumour’s unique biology.’

The study is the largest dataset of patients treated with anti-PD-1-based therapies to be published to date, and this data is now available for use by researchers and clinicians internationally.

Identifying hidden melanoma
07 Jul 2017

Identifying hidden melanoma

New MIA research revealed dermoscopy features that can help detect desmoplastic melanoma.

60 Minutes' MIA Patient Feature Program
04 Jul 2017

60 Minutes' MIA Patient Feature Program

Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here

Training our future melanoma experts
22 Jun 2017

Training our future melanoma experts

Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.

Update from ASCO 2017
17 Jun 2017

Update from ASCO 2017

Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.

Diagnosing melanoma of the mouth
16 Jun 2017

Diagnosing melanoma of the mouth

MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.

New practice-changing research will reduce the need for major surgery in many melanoma patients
09 Jun 2017

New practice-changing research will reduce the need for major surgery in many melanoma patients

New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.

MIA researchers to share new findings at world's largest cancer conference
25 May 2017

MIA researchers to share new findings at world's largest cancer conference

Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.

Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
18 May 2017

Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours

Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.

Melanoma March 2017 wraps up!
12 May 2017

Melanoma March 2017 wraps up!

Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen. 

Melanoma March 2017 helping kick start the Big Data for Melanoma national Research Project!
11 May 2017

Melanoma March 2017 helping kick start the Big Data for Melanoma national Research Project!

Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!

Whole genome sequencing finds unexpected genomic landscape in melanoma
10 May 2017

Whole genome sequencing finds unexpected genomic landscape in melanoma

By looking at the ‘dark matter’ of the genome, new research has found that genetic changes in acral and mucosal melanoma are completely different to mutations found in skin melanoma.

Shining a light on melanomas that aren't caused by the sun
04 May 2017

Shining a light on melanomas that aren't caused by the sun

‘Slip, slop, slap’ is synonymous with being Australian and playing it safe in the sun. These sun smart rules reduce our chances of getting melanoma of the skin. However, new research tells a different story for those affected by rarer forms of melanoma.

New research which more accurately predicts survival for melanoma patients
19 Apr 2017

New research which more accurately predicts survival for melanoma patients

Using MIA's patient database, researchers have developed conditional survival estimates for Stage III melanoma patients to more accurately predict survival outcomes.

Celebrating 60 years of melanoma research to save lives
19 Apr 2017

Celebrating 60 Years of melanoma research to save lives

MIA is proud to be celebrating an important milestone – the 60th anniversary of melanoma research and Australian-led global efforts to find a cure.

Celebrating our research achievements
07 Apr 2017

Celebrating our research achievements

Research achievements by MIA were celebrated at the annual Sydney Medical School recently.

Global Melanoma Research Report - April
06 Apr 2017

Global Melanoma Research Report - April

In this Global Research Report we showcase advances in medical oncology, reveal unexpected pathology in acral and skin melanoma, and uncover biomarkers and new gene targets for melanoma.

The people behind the Professors
29 Mar 2017

The people behind the Professors

Professor’s Long and Scolyer are well known in the academic community and beloved by their patients. But we wanted to get to know our new Conjoint Medical Directors a little more and hear their plans on making an impact on melanoma.

Wyong Rugby Leagues kicks goal to help end melanoma
28 Mar 2017

Wyong Rugby Leagues kicks goal to help end melanoma

Wyong Rugby League Club Group has joined forces with Melanoma Institute Australia to help end melanoma for future generations.

Melanoma research reaches a milestone
21 Mar 2017

Melanoma research reaches a milestone

Melanoma research has reached a milestone with the 10,000th patient giving their permission for their blood and tissue samples to be used in the world’s largest melanoma biospecimen bank. 

Contributing to the promise of Surgical Oncology
17 Mar 2017

Contributing to the promise of Surgical Oncology

MIA's researchers and clinicians are in Seattle, USA, today sharing their research findings at the prestigious Society of Surgical Oncology’s Annual Cancer Symposium.